Beyond A Single Study Visit: Lesson Learned from the AD Clinical Trials

Abstract

Background: Recent clinical trials for Alzheimer’s disease have provided key insights: (i) the treatment effect is relatively proportional across post‐baseline visits; and (ii) consistent effects can be observed across primary and secondary endpoints.

The paper